anti allergic agents


Summary: Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)

Top Publications

  1. Mailhol C, Lauwers Cances V, Rance F, Paul C, Giordano Labadie F. Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children. Allergy. 2009;64:801-6 pubmed publisher
    ..Risk factors associated with sensitization to AD topical treatments are AD severity, early AD onset and IgE-mediated sensitization. ..
  2. Kanai K, Asano K, Watanabe S, Kyo Y, Suzaki H. Epinastine hydrochloride antagonism against interleukin-4-mediated T cell cytokine imbalance in vitro. Int Arch Allergy Immunol. 2006;140:43-52 pubmed
    ..The present results strongly suggest that EP, a second-generation H1 receptor antagonist, interferes with IL-4-activated signaling in CD4+ T cells and results in favorable modification of the allergic disease state or conditions. ..
  3. Murray B, Biagioni P, Lamey P. The efficacy of amlexanox OraDisc on the prevention of recurrent minor aphthous ulceration. J Oral Pathol Med. 2006;35:117-22 pubmed
    ..Erythema score, ulcer size, pain scores and thermographically active area and temperature all showed trends towards healing in the OraDisc group. The OraDisc prevents ulcers from developing when compared with the vehicle patch. ..
  4. Price D, Bond C, Bouchard J, Costa R, Keenan J, Levy M, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis. Prim Care Respir J. 2006;15:58-70 pubmed
  5. Liu J, Zeng X, Chen Q, Cai Y, Chen F, Wang Y, et al. An evaluation on the efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulceration in a Chinese cohort: a randomized, double-blind, vehicle-controlled, unparallel multicenter clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:475-81 pubmed
    ..05). No systemic side effects were reported. Amlexanox oral adhesive tablets are effective and safe in reducing aphthous ulcer pain and lesion size, as well as erythema and exudation in this Chinese cohort. ..
  6. Sato H, Nave R, Nonaka T, Mochizuki T, Takahama S, Kondo S. In vitro metabolism of ciclesonide in human nasal epithelial cells. Biopharm Drug Dispos. 2007;28:43-50 pubmed
    ..In conclusion, ciclesonide was rapidly converted to des-CIC by carboxylesterases and cholinesterases, and des-CIC underwent reversible fatty acid conjugation in HNEC. ..
  7. Rizzo M, Sole D. Inhaled corticosteroids in the treatment of respiratory allergy: safety vs. efficacy. J Pediatr (Rio J). 2006;82:S198-205 pubmed
    ..ICS are the main anti-inflammatory agent used to treat persistent asthma. When administered in low doses, they seem to be safe and effective. Patient monitoring allows for early detection of possible side effects associated with ICS. ..
  8. Barnes M, Menzies D, Fardon T, Burns P, Wilson A, Lipworth B. Combined mediator blockade or topical steroid for treating the unified allergic airway. Allergy. 2007;62:73-80 pubmed
    ..The relevance of this to exacerbations and airway remodelling needs to be defined. ..
  9. Rodriguez M, Rubio J, Sanchez R. Effectiveness of two oral pastes for the treatment of recurrent aphthous stomatitis. Oral Dis. 2007;13:490-4 pubmed
    ..No statistical differences between groups of the study medications were found. The two treatments applied had similar effectiveness as they both relieved pain and reduced the size of recurrent aphthous ulcers. ..

More Information


  1. Hirano T, Kawai M, Arimitsu J, Ogawa M, Kuwahara Y, Hagihara K, et al. Preventative effect of a flavonoid, enzymatically modified isoquercitrin on ocular symptoms of Japanese cedar pollinosis. Allergol Int. 2009;58:373-82 pubmed publisher
    ..Intake of the quercetin glycoside EMIQ proved to be effective for the relief of ocular symptoms caused by Japanese cedar pollinosis. ..
  2. Dridi D, Ben Attia M, Sani M, Djebli N, Sauvage F, Boughattas N. Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. Chronobiol Int. 2008;25:533-47 pubmed publisher
    ..39 and 1252.53 (ng/mL) . h, respectively). These pharmacokinetic data indicate that the administration time of loratadine significantly affected its pharmacokinetics: the elimination of loratadine and its major metabolite desloratadine. ..
  3. Popović G, Cakar M, Agbaba D. Acid-base equilibria and solubility of loratadine and desloratadine in water and micellar media. J Pharm Biomed Anal. 2009;49:42-7 pubmed publisher
    ..The results revealed a shift of pK(a) values in micellar media comparing to the values obtained in water. These shifts (DeltapK(a)) ranged from -2.24 to +1.24. ..
  4. Choi Y, Yan G. Anti-allergic effects of scoparone on mast cell-mediated allergy model. Phytomedicine. 2009;16:1089-94 pubmed publisher
    ..Our findings suggest that scoparone may serve as an effective therapeutic agent for allergic diseases. ..
  5. Jeon J, Kwon S, Park D, Shin S, Jeong J, Park S, et al. Anti-allergic effects of white rose petal extract and anti-atopic properties of its hexane fraction. Arch Pharm Res. 2009;32:823-30 pubmed publisher
    ..In conclusion, these results suggest that either the hexane fraction or one of its components may be beneficial for the treatment of allergic diseases, including atopic dermatitis. ..
  6. Lovern M, Sargentini Maier M, Otoul C, Watelet J. Population pharmacokinetic and pharmacodynamic analysis in allergic diseases. Drug Metab Rev. 2009;41:475-85 pubmed publisher
    ..Population PK/PD models have most frequently been applied to analyzing and interpreting data from wheal and flare trials, but are also becoming increasingly important in the analysis of PD data from monoclonal antibodies. ..
  7. Khan M, Abou Halawa A, Al Robaee A, Alzolibani A, Al Shobaili H. Daily versus self-adjusted dosing of topical mometasone furoate nasal spray in patients with allergic rhinitis: randomised, controlled trial. J Laryngol Otol. 2010;124:397-401 pubmed publisher
    ..Self-adjusted dosage of mometasone furoate nasal spray gives reasonable control of allergic rhinitis (albeit with some 'breakthrough' symptoms). Patients should learn how to control these symptoms with the least number of steroid doses. ..
  8. Wolthers O. Relevance of pharmacokinetics and bioavailability of intranasal corticosteroids in allergic rhinitis. Recent Pat Inflamm Allergy Drug Discov. 2010;4:118-23 pubmed
    ..Evidence for intranasal corticosteroids in pre-school children has not been provided. In this paper, a brief review of recent patents for the treatment of allergic rhinitis has also been presented. ..
  9. Bachert C, Maurer M. Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin Drug Investig. 2010;30:109-22 pubmed publisher
    ..A post hoc analysis of subjects who had received previous monotherapy with a second-generation antihistamine found that most subjects rated efficacy as higher than their previous treatment, with a faster onset of symptom relief. ..
  10. Yazid S, Ayoub S, Solito E, McArthur S, Vo P, Dufton N, et al. Anti-allergic drugs and the Annexin-A1 system. Pharmacol Rep. 2010;62:511-7 pubmed
    ..Some of the implications of this finding are discussed. ..
  11. Kassuya C, Rogerio A, Calixto J. The role of ET(A) and ET(B) receptor antagonists in acute and allergic inflammation in mice. Peptides. 2008;29:1329-37 pubmed publisher
    ..However, both ET(A) and ET(B) receptor antagonists were found to be effective in inhibiting the allergic response in a murine model of asthma. ..
  12. Simons F. Emergency treatment of anaphylaxis. BMJ. 2008;336:1141-2 pubmed publisher
  13. Laekeman G, Simoens S, Buffels J, Gillard M, Robillard T, Benedetti M, et al. Continuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practice. Respir Med. 2010;104:615-25 pubmed publisher
    ..With regard to the cost and cost-effectiveness implications of continuous therapy versus on-demand therapy, more studies are necessary before definitive conclusions may be made. ..
  14. Wahn U, Martin C, Freeman P, Blogg M, Jimenez P. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy. 2009;64:1780-7 pubmed publisher
    ..While previous analyses have had some limited success in predicting which patients will gain greatest benefit based on pretreatment baseline characteristics, it remains important to try to improve this predictability...
  15. van Bavel J, Howland W, Amar N, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30:512-8 pubmed publisher
    ..5%) and nasal discomfort (4.5%), adverse events with azelastine 0.15% were reported with an incidence similar to placebo. Azelastine 0.15% nasal spray was effective and well tolerated in subjects with SAR with once-daily dosing. ..
  16. Kelso J. Combination therapy with azelastine and fluticasone nasal sprays. Ann Allergy Asthma Immunol. 2008;101:111 pubmed publisher
  17. Patel D, Ratner P, Clements D, Wu W, Faris M, Philpot E. Lack of effect on adult and adolescent hypothalamic-pituitary-adrenal axis function with use of fluticasone furoate nasal spray. Ann Allergy Asthma Immunol. 2008;100:490-6 pubmed publisher
    ..Plasma levels of fluticasone furoate were undetectable after 6 weeks of treatment. Fluticasone furoate nasal spray, 110 microg once daily, was not associated with HPA axis suppression in patients 12 years and older with perennial AR. ..
  18. Tani H, Hasumi K, Tatefuji T, Hashimoto K, Koshino H, Takahashi S. Inhibitory activity of Brazilian green propolis components and their derivatives on the release of cys-leukotrienes. Bioorg Med Chem. 2010;18:151-7 pubmed publisher
    ..Artepillin C, baccharin, and kaempferide were the major active components of the ethanol extract. The inhibitory activity of artepillin C phenethyl ester was comparable to that of existing LT synthesis inhibitors. ..
  19. Lee J, Lim K. Inhibitory effect of phytoglycoprotein (24kDa) on allergy-related factors in compound 48/80-induced mast cells in vivo and in vitro. Int Immunopharmacol. 2010;10:591-9 pubmed publisher
    ..Taken together, we speculate that the ZPDC glycoprotein might be one component found in natural products that has the ability to prevent dysfunction in the immune system caused by several different allergens...
  20. Zhao Y, Woo K, Ma K, van Hansselt C, Wong K, Cheng K, et al. Treatment of perennial allergic rhinitis using Shi-Bi-Lin, a Chinese herbal formula. J Ethnopharmacol. 2009;122:100-5 pubmed publisher
    ..The improvement was sustained for at least 2 weeks after treatment. No serious adverse events were encountered. ..
  21. Li Y, Lee S, Le Q, Kim M, Kim S. Anti-allergic effects of phlorotannins on histamine release via binding inhibition between IgE and Fc epsilonRI. J Agric Food Chem. 2008;56:12073-80 pubmed publisher
    ..These results suggested that compounds 1 and 3 could be the key effectors in the crude methanol extract of EC against allergy disease and used as novel candidates for development in the cosmetic and drug industries potentially. ..
  22. Knipping K, van Esch E, Wijering S, van der Heide S, Dubois A, Garssen J. In vitro and in vivo anti-allergic effects of Arctium lappa L. Exp Biol Med (Maywood). 2008;233:1469-77 pubmed publisher
    ..In addition, this active component was able to inhibit acute skin response in mice in vivo, indicating that AL is a very promising natural component for use in anti-allergic treatment. ..
  23. Meltzer E, Andrews C, Journeay G, Lim J, Prillaman B, Garris C, et al. Comparison of patient preference for sensory attributes of fluticasone furoate or fluticasone propionate in adults with seasonal allergic rhinitis: a randomized, placebo-controlled, double-blind study. Ann Allergy Asthma Immunol. 2010;104:331-8 pubmed publisher
    ..Most patients preferred the sensory attributes of fluticasone furoate to those of fluticasone propionate after 1 week of treatment. ..
  24. Agarwal M, Vijayan V, Vermani M. Effect of azelastine nasal spray on histamine-and allergen-induced skin wheal response in patients with allergic rhinitis. J Asthma. 2008;45:548-51 pubmed publisher
    ..05). It is concluded that diagnostic allergen skin tests may be performed on patients undergoing azelastine nasal spray treatment (0.28 mg/dose, twice a day) during their symptomatic period. ..
  25. Lappin G, Shishikura Y, Jochemsen R, Weaver R, Gesson C, Houston B, et al. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci. 2010;40:125-31 pubmed publisher
    ..35 (microdose 0.41, therapeutic dose 0.30). Despite a 1200-fold difference in dose of fexofenadine, the microdose predicted well the pharmacokinetic parameters following a therapeutic dose for this transporter dependent compound. ..
  26. McNally K, Rohan J, Schluchter M, Riekert K, Vavrek P, Schmidt A, et al. Adherence to combined montelukast and fluticasone treatment in economically disadvantaged african american youth with asthma. J Asthma. 2009;46:921-7 pubmed publisher
    ..001), but not fluticasone adherence. These results suggest that adherence promotion intervention strategies are warranted to improve health-related outcomes in families who are at-risk for treatment nonadherence. ..
  27. Schroder S, Surmann P. Photoallergenic potential testing by online irradiation and HPLC. Pharmazie. 2010;65:339-42 pubmed
    ..The screening was performed at pH 3 and pH 7. Both cleavage of the peptide binding and formation of new products could indicate a photoallergenic potential...
  28. Khan D. Chronic urticaria: diagnosis and management. Allergy Asthma Proc. 2008;29:439-46 pubmed publisher
    ..The ultimate goal should be to control urticaria to reduce its impact on the quality of life of the patient, minimize adverse effects of medications, and eliminate chronic or frequent oral corticosteroids. ..
  29. Itoh K, Masuda M, Naruto S, Murata K, Matsuda H. Antiallergic activity of unripe Citrus hassaku fruits extract and its flavanone glycosides on chemical substance-induced dermatitis in mice. J Nat Med. 2009;63:443-50 pubmed publisher
    ..Other combinations of prednisolone (s.c.) and flavanone glycoside (p.o.) components of CH-ext, i.e. naringin and neohesperidin, exerted similar synergistic effects. ..
  30. Poggesi I, Benedetti M, Whomsley R, Le Lamer S, Molimard M, Watelet J. Pharmacokinetics in special populations. Drug Metab Rev. 2009;41:422-54 pubmed publisher
    ..It is important to recognize that both pharmacokinetic and pharmacodynamic differences between populations should be considered. The available information on drugs used for the therapy of allergic diseases is reviewed in this chapter. ..
  31. Asano K, Furuta A, Kanai K, Sakaue S, Suzaki H, Hisamitsu T. Inhibition of angiogenic factor production from murine mast cells by an antiallergic agent (epinastine hydrochloride) in vitro. Mediators Inflamm. 2008;2008:265095 pubmed publisher
    ..These results strongly suggest that EP suppresses angiogenesis factor production through the inhibition of mRNA expression in mast cells and results in favorable modification of clinical conditions of allergic diseases. ..
  32. Tennyson D. Predicting medication costs and usage: expenditures in a juvenile detention facility. J Correct Health Care. 2009;15:98-104; quiz 159 pubmed publisher
    ..50 per youth. Male youths who were prescribed medications cost $324 per month; their female counterparts cost $170 per month. ..
  33. Choi Y, Yan G. Pycnogenol inhibits immunoglobulin E-mediated allergic response in mast cells. Phytother Res. 2009;23:1691-5 pubmed publisher
    ..Furthermore, PYC suppressed nuclear factor-kappa B activation. From these results, the clinical use of PYC in the mast cell-mediated immediate-type allergic diseases is proposed. ..
  34. Ishii Y, Nozawa R, Takamoto Matsui Y, Teng A, Katagiri Matsumura H, Nishikawa H, et al. Alpha-galactosylceramide-driven immunotherapy for allergy. Front Biosci. 2008;13:6214-28 pubmed
  35. Phan H, Moeller M, Nahata M. Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Drugs. 2009;69:2541-76 pubmed publisher
  36. Brinkhaus B, Witt C, Ortiz M, Roll S, Reinhold T, Linde K, et al. Acupuncture in seasonal allergic rhinitis (ACUSAR)--design and protocol of a randomised controlled multi-centre trial. Forsch Komplementmed. 2010;17:95-102 pubmed publisher
    ..The results of this trial available in 2011 will have a major impact on the decision of whether acupuncture should be considered as a therapeutic option in the treatment of SAR. ..
  37. Bar Sela G, Kedem E, Hadad S, Pollack S, Haim N, Atrash F, et al. Successful desensitization protocol for hypersensitivity reaction caused by sunitinib in a patient with a gastrointestinal stromal tumor. Jpn J Clin Oncol. 2010;40:163-5 pubmed publisher
    ..Oral desensitization appears to be an option for patients with hypersensitivity type I to sunitinib and may permit its safe administration to patients who experience HSR to this life-prolonging medication. ..
  38. Engelhardt H, Smits R, Leurs R, Haaksma E, De Esch I. A new generation of anti-histamines: Histamine H4 receptor antagonists on their way to the clinic. Curr Opin Drug Discov Devel. 2009;12:628-43 pubmed
    ..The first clinical candidates targeting the H4R have been identified, and new H4R antagonists are expected to enter the clinic in the near future. ..
  39. Mehta V, Stokes J, Berro A, Romero F, Casale T. Time-dependent effects of inhaled corticosteroids on lung function, bronchial hyperresponsiveness, and airway inflammation in asthma. Ann Allergy Asthma Immunol. 2009;103:31-7 pubmed publisher
    ..50, P < .001). The F(ENO) level responded the earliest to treatment and withdrawal of inhaled corticosteroids, whereas changes in EBC markers were delayed but more sustained. ..
  40. Bielory L. American Academy of Allergy, Asthma & Immunology--2008 Annual Meeting. IDrugs. 2008;11:309-11 pubmed
  41. Nakanishi K, Tsutsui H, Yoshimoto T. Importance of IL-18-induced super Th1 cells for the development of allergic inflammation. Allergol Int. 2010;59:137-41 pubmed publisher
    ..Based on this unique function of Ag- plus IL-18-stimulated Th1 cells, we proposed to designate them as "super Th1 cells". ..
  42. Weiss K, Gern J, Johnston N, Sears M, Jones C, Jia G, et al. The Back to School asthma study: the effect of montelukast on asthma burden when initiated prophylactically at the start of the school year. Ann Allergy Asthma Immunol. 2010;105:174-81 pubmed publisher
    ..The effect of montelukast treatment on the fall peak in asthma burden may depend on sex, age, and the date of school return. ..
  43. Broide D. New perspectives on mechanisms underlying chronic allergic inflammation and asthma in 2007. J Allergy Clin Immunol. 2008;122:475-80 pubmed publisher
  44. Torkildsen G, Abelson M, Gomes P. Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis. Clin Ther. 2008;30:1272-82 pubmed
    ..025% met criteria for bioequivalence to the reference formulation, as established by the protocol. The test and reference formulations were well tolerated in the population studied. ..
  45. Bae S, Lee J, Shimizu K, Kuwazuka Y. Increase effect of transforming growth factor on eotaxin production by normal cultured dermal fibroblasts stimulated with interleukin-4: inhibitory effect of suplatast tosilate on eotaxin production. Immunol Invest. 2010;39:93-102 pubmed publisher
    ..These results suggest that TGF-beta may regulate skin allergic inflammation by up-regulating eotaxin production in dermal fibroblasts. Suplatast tosilate might suppress this inflammation by inhibiting eotaxin production. ..
  46. Lee B, Trinh H, Jung K, Han S, Kim D. Inhibitory effects of steroidal timosaponins isolated from the rhizomes of Anemarrhena asphodeloides against passive cutaneous anaphylaxis reaction and pruritus. Immunopharmacol Immunotoxicol. 2010;32:357-63 pubmed publisher
    ..On the basis of these findings, antiallergic effect of AA may be due to those of its steroidal constituents, and that of timosaponin AIII may be activated by using intestinal microflora...
  47. Hofmann A, Scurlock A, Jones S, Palmer K, Lokhnygina Y, Steele P, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol. 2009;124:286-91, 291.e1-6 pubmed publisher
    ..Subjects were more likely to have significant allergic symptoms during the initial escalation day when they were in a closely monitored setting than during other phases of the study. Allergic reactions with home doses were rare. ..
  48. Kim S, Kim J, Kim Y, Lee S, Yoon H, Kim C, et al. Effects of tranilast and pentoxifylline in a mouse model of chronic asthma using house dust mite antigen. J Asthma. 2009;46:884-94 pubmed publisher
    ..These drugs could have potential beneficial effects on chronic asthma, especially with respect to airway remodeling. ..
  49. Bonini S, Craig T. The elite athlete: yes, with allergy we can. J Allergy Clin Immunol. 2008;122:249-50 pubmed publisher
  50. Nonaka M, Sakanushi A, Kusama K, Ogihara N, Yagi T. One-year evaluation of combined treatment with an intranasal corticosteroid and montelukast for chronic rhinosinusitis associated with asthma. J Nippon Med Sch. 2010;77:21-8 pubmed
    ..578, p=0.012) and 12 months (r=0.625, p=0.007). Combined treatment with intranasal fluticasone propionate and montelukast, for at least 1 year, is effective for chronic rhinosinusitis associated with adult-onset asthma. ..
  51. Di Landro A, Marchesi L, Passera M, Arosio M. Tinea capitis due to Trichophyton soudanense with a papular IDE reaction in Northern Italy. G Ital Dermatol Venereol. 2008;143:421-4 pubmed
  52. Terracciano L, Calcinai E, Avitabile S, Galli E. Age and indications to SLIT. Int J Immunopathol Pharmacol. 2009;22:5-8 pubmed
    ..Some studies demonstrate that SLIT is safe in children below 5 years of age, with a lower limit of 3 years. ..
  53. Smith S, Gums J. Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opin Drug Metab Toxicol. 2009;5:813-22 pubmed publisher
    ..In addition, fexofenadine may offer cost savings over other selected H(1)-antihistamines owing to its recent availability in generic form in the US. ..